Lunai Bioworks Harnesses AI and Zebrafish Data to Advance Early Detection of Neurotoxic CompoundsNEW YORK, NY / ACCESS Newswire / October 30, 2025 / In the face of growing global concern over the potential use of chemical weapons such as the nerve agent Sarin, Lunai Bioworks Inc. (
NASDAQ:LNAI) today announced promising early results from its AI-based platform designed to identify compounds that interact with acetylcholinesterase (AChE), the same molecular target affected by nerve agents.
Landmark Study Identifies Prognostic Biomarkers in Duchenne Muscular Dystrophy Using Large-Scale Serum ProteomicsPublished in Nature Communications, a new study uncovers critical protein biomarkers that predict functional decline in Duchenne Muscular Dystrophy (DMD), opening doors to more personalized care and improved clinical trials.
Lunai Bioworks Regains Compliance with Nasdaq Minimum Bid Price RequirementLOS ANGELES, CALIFORNIA / ACCESS Newswire / October 16, 2025 / Lunai Bioworks, Inc. (Nasdaq:LNAI), today announced that it has regained compliance with Nasdaq's minimum bid price requirement.
Lunai Bioworks Launches AI-Powered Alzheimer's Disease Program, Expanding Neurodegenerative PipelineLOS ANGELES, CALIFORNIA / ACCESS Newswire / October 6, 2025 / Lunai Bioworks (Nasdaq:LNAI) today announced a major advance in Alzheimer's research: its AI platform, Augusta™, achieved up to a 35% improvement in diagnostic accuracy by combining MRI scans with genetic and metabolic data. The company is launching a preclinical Alzheimer's program to bring this technology closer to clinical use, a move that could enable earlier intervention for millions worldwide.
